N eoadjuvant therapy improves survival for patients with resectable gastroesophageal (GE) junction and gastric adenocarcinoma. 1, 2 Preoperative therapy may be more appropriate for patients who are at higher risk for systemic failure as patients with early-stage disease have a high chance of cure with surgical resection alone. 3 Thus, accurate pretreatment staging is essential to inform the decision about neoadjuvant therapy. Unfortunately, preoperative staging methods such as serum tumor markers, endoscopic ultrasound (EUS), and computed tomography (CT) scans are only moderately accurate. [4] [5] [6] [7] More tools to risk stratify patients before treatment initiation are needed.
The patient's inflammatory state is thought to be associated with oncologic outcomes, as suggested by the consistent association of decreased disease-specific survival (DSS) with postoperative complications [8] [9] [10] [11] or the presumed immunomodulatory effect of red blood cell transfusions. [12] [13] [14] Systemic inflammation leads to relative neutrophilia and lymphocytopenia. [15] [16] [17] As a result, the neutrophil to lymphocyte ratio (NLR) has been used as a simple and convenient marker for the systemic inflammatory response. 15 Elevated NLR is associated with worse survival in wide variety of malignancies including colorectal cancer, 18 pancreatic cancer, 19 gastrointestinal stromal tumor, 20 hepatocellular carcinoma, 21 non-small cell lung cancer, 22 ovarian cancer, 23 multiple myeloma, 24 and renal cell carcinoma. 25 Previous studies have also linked NLR to gastric cancer outcomes. [26] [27] [28] However, these reports are hampered by small sample size or limited statistical analyses. The aim of this study was to evaluate the relationship between DSS and pretreatment NLR in a large uniform cohort of patients with curatively resected GE junction and gastric adenocarcinomas in an effort to identify a new tool to risk-stratify patients to aid in clinical decision making.
PATIENTS AND METHODS
A retrospective review of a prospectively maintained database was performed to identify all patients who underwent potentially curative resection for GE junction and gastric adenocarcinoma between 1998 and 2013 at Memorial Sloan Kettering Cancer Center (MSKCC). Patients with M1 disease, nonprimary adenocarcinoma, or without pretreatment complete blood count values were excluded. Clinicopathologic findings and follow-up status were documented. Neutrophil, lymphocyte, and monocyte values obtained before the initiation of any treatment (surgery, chemotherapy, or radiation) were recorded. For patients who underwent neoadjuvant therapy, posttreatment, preoperative leukocyte counts were also obtained. All laboratories' values were measured within 3 months of initial treatment. The MSKCC institutional review and privacy board approved the study.
Disease-specific survival was calculated from date of surgery to date of death from gastric cancer. Patients who died of causes unrelated to the disease were censored at the last follow-up. Survival was estimated by Kaplan-Meier methods. Multivariate Cox proportional hazards model was used to examine the effect of pretreatment NLR as a continuous variable on DSS after adjusting for known confounders: age at surgery, T stage, N stage, and tumor location. 29 The log-rank test was used to compare DSS between groups when the patients were stratified into quartiles based on NLR.
For patients who received neoadjuvant therapy, we used the sign test, which is a nonparametric method that determines whether the medians of 2 continuous variables are different from each other in the presence of paired data (ie, before and after treatment), to evaluate the difference in median white blood cell before and after neoadjuvant therapy. 30, 31 All analyses were carried out using SAS (version 9.2, SAS Institute Inc, Cary, NC).
RESULTS

Elevated NLR Was Associated With Worse DSS
A total of 1848 patients were initially identified. We excluded 151 patients who had M1 disease or nonprimary adenocarcinoma and 199 patients who did not have pretreatment laboratory values available. The study cohort consisted of 1498 patients and the median follow-up was 4 years. The median age was 66 years, with a range of 20 to 96. The median NLR was 2.8 [range, 0.2-30.3; interquartile range (IQR): 2.0-3.9]. Median time from laboratory measurement to initiation of neoadjuvant therapy or operation was 7 days (range: 1-67 days; IQR: 4-13 days). A total of 187 patients were censored at last follow-up for death unrelated to disease.
Univariate associations of clinicopathologic characteristics and treatment patterns to DSS are outlined in Table 1 . Male sex, Caucasian race, proximal tumor location, tumor dedifferentiation, diffuse type histology, vascular involvement, perineural invasion, and higher T and N stages were significantly associated with worse outcomes (all P < 0.01).
The associations of leukocyte counts with DSS are detailed in Table 2 . Elevated neutrophil [hazard ratio (HR ¼ 1.15; 95% CI: 1.10-1.19; P < 0.01] and monocyte (HR ¼ 2.64; 95% CI: 1.62-4.33; P < 0.01) counts were associated with worse DSS whereas increased lymphocytes were associated with improved survival (HR ¼ 0.80; 95% CI: 0.69-0.94; P < 0.01). NLR was also significantly associated with worse DSS (HR ¼ 1.11; 95% CI: 1.08-1.14; P < 0.01).
Elevated NLR Was Associated With Unfavorable Clinicopathologic Factors
We next assessed whether NLR was associated with patient and tumor characteristics ( Table 3) . Elevated NLR was related to many clinicopathologic variables previously shown to be associated with worse outcomes in GE junction and gastric adenocarcinomas. 29 Median NLR were significantly higher in patients who were male, older than 66 years, and of Caucasian race. Patients with tumors at the GE junction, higher T stage, and higher N stage also had elevated NLR (all P < 0.01).
Other pathologic factors associated with increased NLR were moderate/poor differentiation, intestinal Lauren histology, and vascular invasion. Although statistically significant, the absolute difference in NLR for these characteristics was smaller (10% change or less).
For the 508 patients who underwent neoadjuvant therapy, there was a significant reduction in both neutrophil [À1.3 K/mL (À27%); P < 0.01] and lymphocyte [À0.4 K/mL (À25%); P < 0.01] counts after treatment. However, NLR did not change significantly (À0.1; P ¼ 0.86) ( Table 4 ).
NLR Independently Predicted DSS
Finally, we performed a multivariate analysis to determine if NLR independently predicted DSS (Table 5 ). After adjusting for age at surgery, T stage, N stage, and tumor location, we found that pretreatment NLR as a continuous variable was independently associated with DSS (HR ¼ 1.10; 95% CI: 1.05-1.13; P < 0.0001). Tumor location, T stage, and N stage (all P < 0.0001) also independently correlated with DSS. Analyses including pretreatment monocyte count in the above multivariate model showed that it was not significantly associated with DSS (HR ¼ 1.20; 95% CI: 0.70-2.01; P ¼ 0.52). Even when we excluded pretreatment NLR, there was still no significant association between monocyte count and DSS (HR ¼ 1.35; 95% CI: 0.78-2.36; P ¼ 0.29). Long-term DSS is shown for patients on the basis of NLR stratified into quartiles (P < 0.01; Fig. 1 ).
DISCUSSION
This report is the largest series to show that NLR is an independent predictor of disease-specific outcome in any cancer population. We found that elevated NLR is associated with a number of variables previously shown to be predictive of worse outcomes. These include patient characteristics such as male sex, older age, and Caucasian race and tumor features including higher T and N stage, poor differentiation, GE junction location, and vascular invasion. However, we also found that NLR as a continuous variable independently predicted DSS, which suggests that NLR may be a predictor of oncologic outcomes and may aid in the clinical decision-making process. We estimate that for every unit increase in NLR, there is an approximately 10% rise in risk for cancer-related death.
Previous reports on NLR were constrained by small or limited patient populations or the use arbitrary cutoff values. Specifically for gastric cancer, Yamanaka et al 32 studied the association of NLR to survival in 1220 nonsurgical patients with stage 4 disease who were enrolled in prospective trials to evaluate the efficacy of S-1, whereas Shimada et al 33 evaluated 1028 patients with primary gastric adenocarcinoma who underwent gastrectomy. Although both groups found that NLR was associated with survival, they dichotomized the study population with an arbitrary cutoff value limiting the statistical power of their analyses. This is also the largest report with patients who underwent neoadjuvant therapy. Preoperative systemic treatment for locoregional advanced gastric cancer significantly improves overall survival and is now widely utilized in the Western world. 1 We found that patients who received neoadjuvant therapy had higher median pretreatment NLR than patients who did not receive therapy. This is likely because patients who underwent systemic therapy tended to have higher stage disease. Indeed, we found that even though neutrophil and lymphocyte counts were significantly reduced after neoadjuvant therapy, the posttreatment, preoperative NLR was not significantly different than pretreatment NLR and remained independently predictive of DSS (data not shown).
Accurate risk stratification is essential to determine if a given patient should receive preoperative systemic therapy. Overstaging unnecessarily exposes the patient to the morbidity of chemotherapy while understaging risks missing the opportunity to administer preoperative systemic therapy, as many patients cannot tolerate adjuvant therapy after gastrectomy. [34] [35] [36] Currently, the most widely utilized preoperative staging tools are EUS and CT scans, both of which are of only modest utility. In a systematic review of the literature, Kwee and Kwee 37 reported that accuracy in determining T stage ranged from 65% to 92% for EUS and 77% to 88% for CT scans. For nodal disease, they reported that median sensitivity and specificity for EUS were 71% and 85%, respectively, and 80% and 78%, respectively, for CT scans. However, the range for each measure was very wide. 38 One of the main limitations of EUS is its high operator dependency. Bentrem et al reviewed the utility of EUS staging in predicting pathologic findings and outcomes. They found that EUS was only 57% accurate in determining individual T stage and only 50% accurate for N stage. More importantly, they noted only a modest predictive value in discriminating outcome when comparing uT 1-3 N 0 with T 4a N any patients. 7 In addition, most reports on the staging utility of EUS and CT scan seem to be too optimistic as suggested by a population-wide analysis of gastric cancer treatment pattern reporting that up to 30% of patients have occult metastatic disease not appreciated on preoperative staging evaluation. 39 In light of the limitations of EUS and CT scans, NLR could be a useful and easily obtainable variable to include in the preoperative evaluation of GE junction and gastric cancer patients. NLR could be especially important to help decide about neoadjuvant therapy in patients who are considered to be borderline candidates based on conventional imaging techniques.
Previous studies showed that pretreatment levels of carcinoembryonic antigen, certain acute phase reactants, and nutritional markers independently predict outcomes in gastric cancer patients. 4, 40 Our study demonstrated that pretreatment NLR should be included on the list of pretreatment factors that independently predicted disease-specific outcomes after controlling for a wide variety of confounders.
The concept of inflammation as a localized procarcinogenic process dates back to the 19th century with Virchow's observations. Currently, inflammation is thought of as a key enabling process for cells to acquire essential ''hallmarks of cancer'' that constitute the foundation of malignant transformation. 41 However, studies demonstrating independent association of an activated acute inflammatory response and cancer-specific outcomes suggest that there is also a correlation between the systemic inflammatory state, as broadly represented by the neutrophil to lymphocyte ratio, and oncologic progression.
For the surgical patient, infectious complications and blood transfusions are likely the most common postoperative causes of an activated inflammatory state. Multiple reports encompassing a variety of malignancies including breast, 9 esophagus, 10,42 gastric, 11 and colorectal 8, 43 have demonstrated that postoperative complications independently predict worse cancer-specific outcomes. Significantly, these outcomes are not simply related to local recurrence and suggest an underlying systemic process. 9, 11 Similarly, allogenic blood transfusions have also been shown to be independently associated with worse cancer-specific outcomes. 12, 13, 44 Interestingly, Weitz et al 45 showed that in patients who underwent resection for Siewert II or III tumors, blood transfusions are associated with worse DSS only in patients who had an intact spleen, further implicating the immune process as the mediator between transfusions and oncologic outcomes. Several recent studies have provided a number of potential mechanisms to explain the prognostic power of neutrophilia in cancer patients. Bald et al 46 reported that in melanoma, neutrophils infiltrate the primary tumor site and secrete factors that stimulate angiogenesis and induce cancer cells to migrate along these newly formed blood vessels, which may facilitate metastasis. Neutrophils have also been described to increase adhesion between circulating tumor cells and the end-organ, thus increasing the chance of metastatic seeding. Spicer et al 47 described neutrophils acting as an adhesive adapter between circulating tumor cells and the metastatic target. Cools-Lartigue et al 48 noted that neutrophil extracellular traps, which are composed of neutrophil-secreted chromatin and proteins, can capture circulating tumor cells leading to increased metastases in a mouse model.
Lymphopenia has been associated with worse outcomes in cancer patients. 49, 50 Previous studies have shown that lymphocytes may be responsible for generating an antitumor immune response. One example of this thesis is the clinical relevance of tumorinfiltrating lymphocytes, the presence of which is associated with improved outcomes in a variety of cancers, possibly due to tumorinfiltrating lymphocytes-induced anti-tumor activity and inhibition of angiogenesis. [51] [52] [53] The ability of immunotherapy to generate longterm and durable disease response, such as with the case of ipilimumab and melanoma, demonstrate the antioncogenic power of a mobilized adaptive immune system. 54 
CONCLUSIONS
In patients with resectable GE junction and gastric adenocarcinoma, pretreatment NLR is significantly and independently associated with cancer-specific survival. This and other clinical variables can be used to supplement cross-sectional imaging and EUS to better risk stratify patients before treatment.
